A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial.

Trial Profile

A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Ciclosporin (Primary) ; Ciclosporin (Primary) ; Fludarabine (Primary) ; Mycophenolate mofetil (Primary) ; Sirolimus (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Diffuse large B cell lymphoma; Diffuse lymphoma; Follicular lymphoma; Graft-versus-host disease; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma; Mycosis fungoides; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; T cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Nov 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016, according to ClinicalTrials.gov record.
    • 29 Oct 2013 Planned number of patients changed from 35 to 55 as reported by ClinicalTrials.gov.
    • 03 Aug 2012 Additional location (Denmark) and lead trial investigators added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top